Načítá se...
Zanubrutinib-induced liver injury: a case report and literature review
BACKGROUND: Zanubrutinib is a Bruton’s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We repo...
Uloženo v:
| Vydáno v: | BMC Gastroenterol |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8164809/ https://ncbi.nlm.nih.gov/pubmed/34051727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-021-01825-2 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|